Perrigo (NYSE:PRGO) Reaches New 52-Week Low – What’s Next?

Perrigo Company plc (NYSE:PRGO)’s stock price hit a new 52-week low during trading on Friday . The company traded as low as $9.23 and last traded at $9.2450, with a volume of 5586251 shares. The stock had previously closed at $9.65.

Perrigo News Roundup

Here are the key news stories impacting Perrigo this week:

• Neutral Sentiment: Perrigo’s most recent quarterly report (Feb 26) showed a slight revenue miss and an EPS shortfall versus last year; management set FY2026 guidance at $2.25–$2.55. The stock is trading with above-average volume and near its 1‑year low, which may amplify moves on new analyst commentary. MarketBeat Perrigo page
• Negative Sentiment: Zacks Research cut a wide set of EPS estimates across FY2026–FY2028 and lowered quarterly forecasts for Q1–Q4 2026 and multiple quarters in 2027. The firm reduced FY2026 EPS to $2.18 (from $3.00) and FY2027 EPS to $2.53 (from $3.18), reflecting a materially weaker near‑term earnings trajectory. Zacks maintained a “Hold” rating. This broad downdraft in analyst estimates is the primary catalyst for downward pressure on the stock. Zacks estimates summary

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on PRGO shares. Argus upgraded Perrigo to a “hold” rating in a report on Wednesday, January 14th. Jefferies Financial Group reaffirmed a “hold” rating on shares of Perrigo in a report on Thursday, February 26th. JPMorgan Chase & Co. decreased their price target on Perrigo from $20.00 to $18.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. Weiss Ratings restated a “sell (d+)” rating on shares of Perrigo in a research report on Monday, December 22nd. Finally, Zacks Research raised Perrigo from a “strong sell” rating to a “hold” rating in a research note on Friday, February 13th. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $19.33.

Perrigo Price Performance

The stock has a market capitalization of $1.27 billion, a P/E ratio of -0.90, a PEG ratio of 1.11 and a beta of 0.41. The company has a debt-to-equity ratio of 1.23, a quick ratio of 1.63 and a current ratio of 2.76. The business has a fifty day simple moving average of $13.29 and a 200-day simple moving average of $16.06.

Perrigo (NYSE:PRGO) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.77 earnings per share for the quarter, missing the consensus estimate of $0.80 by ($0.03). The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. Perrigo had a negative net margin of 33.51% and a positive return on equity of 9.41%. The business’s revenue was down 2.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.93 EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Sell-side analysts expect that Perrigo Company plc will post 2.56 earnings per share for the current fiscal year.

Perrigo Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 24th. Stockholders of record on Monday, March 2nd will be issued a dividend of $0.29 per share. The ex-dividend date is Monday, March 2nd. This represents a $1.16 annualized dividend and a dividend yield of 12.5%. Perrigo’s dividend payout ratio is currently -11.28%.

Institutional Trading of Perrigo

Several large investors have recently made changes to their positions in the company. Geneos Wealth Management Inc. raised its stake in Perrigo by 439.1% during the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after buying an additional 786 shares during the period. Kestra Investment Management LLC grew its stake in Perrigo by 57.1% in the second quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock valued at $47,000 after acquiring an additional 642 shares during the period. Jones Financial Companies Lllp increased its holdings in shares of Perrigo by 89.1% during the third quarter. Jones Financial Companies Lllp now owns 1,778 shares of the company’s stock valued at $38,000 after acquiring an additional 838 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Perrigo by 116.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after acquiring an additional 1,014 shares in the last quarter. Finally, UMB Bank n.a. raised its position in shares of Perrigo by 161.5% during the fourth quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock worth $27,000 after purchasing an additional 1,213 shares during the period. 95.91% of the stock is currently owned by institutional investors and hedge funds.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.